In response to an aging global population (and possibly in an effort to replace lost Copaxone...

|By:, SA News Editor

In response to an aging global population (and possibly in an effort to replace lost Copaxone revenue), Teva (TEVA +2%) is investing $15M over five years in the development of new treatments for diseases such as Alzheimer's, Huntington's, and Parkinson's. "I am convinced that this effort will yield not just one or two drugs but will yield a great understanding how the brain works," CEO Jeremy Levin says. (PR, Reuters)